Skip to main content

Table 1 Clinical characteristics of 47 patients included in the study. Data presented as n (%) and age, diagnostic delay and disease duration as mean ± S.D

From: Reliability of LoSCAT score for activity and tissue damage assessment in a large cohort of patients with Juvenile Localized Scleroderma

Gender

Variable

No.

30/17

F/M

JLS Subtype

 

No. (%)

Linear Scleroderma

30 (63.8)

limbs/trunk

11(23.4)

face

19 (40.4)

PRS

11(23.4)

ECDS

8 (17)

Circumscribed Morphea

7 (14.9)

Generalized Morphea

4 (8.5)

Mixed

6 (12.8)

Treatment

MTX

21 (44.7)

MTX, MMF

3 (6.4)

PDN

1 (2.1)

Age (yrs.)

 

mean ± S.D.

At onset

7.34 ± 4.16

At diagnosis

8.57 ± 3.75

At v1a

13.40 ± 5.19

Diagnostic Delay (yrs.)

 

1.23 ± 1.46

Disease Duration at v1a (yrs.)

 

6.06 ± 4.46

  1. av1 first study visit, JLS Juvenile Localized Scleroderma, PRS Parry Romberg Syndrome, ECDS en coup de sabre, MTX Methotrexate, PDN Prednisone, MMF Mycophenolate Mofetil, S.D Standard Deviation